MRVI Stock Analysis: Maravai Lifesciences | NASDAQ

Biotechnology | NASDAQ, USA | Market Cap: 2.585m USD | 12M Return: 132% | US56600D1072 | Charts, Fundamentals & Technical Analysis

Nucleic Acids, ELISA Kits, Capping Technology, Custom Enzymes
Total Rating 48
Safety 75
Buy Signal -0.63
Life Sciences Tools & Services
Sub-Industry Rotation: -17.0
Market Cap: 2.59B
Avg Turnover: 15.9M
Risk 3d forecast
Volatility72.8%
VaR 5th Pctl11.0%
VaR vs Median-7.46%
Reward TTM
Sharpe Ratio1.48
Rel. Str. IBD98.8
Rel. Str. Peer Group95 pctl
Character TTM
Beta1.772
Beta Downside1.878
Hurst Exponent0.528
Choppyness83.2%
Drawdowns 3y
Max DD84.83%
CAGR/Max DD0.17
CAGR/Mean DD0.31
EPS (Earnings per Share) EPS (Earnings per Share) of MRVI over the last years for every Quarter: "2021-09": 0.09, "2021-12": 0.45, "2022-03": 0.54, "2022-06": 0.54, "2022-09": 0.37, "2022-12": 0.35, "2023-03": 0.03, "2023-06": -0.05, "2023-09": -0.01, "2023-12": 0.01, "2024-03": -0.02, "2024-06": -0.0558, "2024-09": -0.02, "2024-12": -0.06, "2025-03": -0.08, "2025-06": -0.08, "2025-09": -0.08, "2025-12": -0.04, "2026-03": 0.01, "2026-06": -0.07, "2026-09": -0.08,
Last SUE: -0.37
Qual. Beats: 0
Revenue Revenue of MRVI over the last years for every Quarter: 2021-09: 204.81, 2021-12: 228.444, 2022-03: 244.293, 2022-06: 242.732, 2022-09: 191.263, 2022-12: 204.713, 2023-03: 79.025, 2023-06: 68.914, 2023-09: 66.865, 2023-12: 74.141, 2024-03: 64.179, 2024-06: 73.4, 2024-09: 65.2, 2024-12: 56.406, 2025-03: 46.85, 2025-06: 47.397, 2025-09: 41.63, 2025-12: 49.866, 2026-03: 65.837, 2026-06: 51.442, 2026-09: 45.851,
Rev. CAGR: -14.22%
Rev. Trend: -87.0%
Last SUE: 0.41
Qual. Beats: 0

Warnings

High Debt/EBITDA With Thin Interest Coverage
High Debt While Negative Cash Flow
Interest Coverage Ratio Critical
Volatile
Below Avwap Earnings

Tailwinds

Rs Leader

Seasonality 6 years of data, until 10/2026

Jan -2.6% 5
Feb -0.3% 0
Mar -0.8% 5
Apr +1.4% 5
May +11.4% 5
Jun +2.4% 22
Jul +0.0% 0
Aug -0.3% 0
Sep +1.3% 5
Oct -5.8% 22
Nov -4.7% 0
Dec +0.3% 5

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.

Description: MRVI Maravai Lifesciences

Maravai LifeSciences Holdings (NASDAQ: MRVI) is a life sciences company that supplies products enabling the development of drug therapies, vaccines, cell and gene therapies, and diagnostics. The company sells globally across North America, Europe, the Middle East, Africa, Asia Pacific, and Latin and Central America, serving biopharmaceutical firms, emerging biotech, academic research institutions, and diagnostics companies.

The business operates through two segments. The TRILINK segment manufactures nucleic acid chemistry products, including reagents for DNA and RNA synthesis, modification, labelling, and purification, along with mRNA, oligonucleotides, CleanCap capping technology, custom enzyme development, and protein labeling/detection research products. The CYGNUS segment provides analytical products for biologic manufacturing process development, including custom antibody and assay development services, HCP ELISA kits, bioprocess impurity and contaminant ELISA kits, viral clearance prediction kits, and ancillary reagents.

Maravai was founded in 2014, is headquartered in San Diego, California, and completed its IPO in November 2020. Within the Life Sciences Tools & Services sub-industry, the company operates as a consumables and services supplier to pharmaceutical and biotechnology R&D and manufacturing workflows rather than developing its own therapeutics, with revenue tied to outsourced research, development, and bioprocess quality control activities across the biopharmaceutical value chain.

Headlines to Watch Out For
  • TRILINK mRNA revenue declines as COVID vaccine demand normalizes
  • CleanCap licensing deals expand high-margin mRNA customer base
  • CYGNUS bioprocess testing grows on biologic manufacturing demand
Piotroski VR-10 (Strict) 1.5
Net Income: -65.7m TTM > 0 and > 6% of Revenue
FCF/TA: -0.06 > 0.02 and ΔFCF/TA -0.83 > 1.0
NWC/Revenue: 55.04% < 20% (prev 150.9%; Δ -95.82% < -1%)
CFO/TA -0.04 > 3% & CFO -25.3m > Net Income -65.7m
Net Debt (136.2m) to EBITDA (20.5m): 6.64 < 3
Current Ratio: 4.05 > 1.5 & < 3
Outstanding Shares: last quarter (148.0m) vs 12m ago 2.61% < -2%
Gross Margin: 38.87% > 18% (prev 20.86%; Δ 18.01% > 0.5%)
Asset Turnover: 28.39% > 50% (prev 21.44%; Δ 6.95% > 0%)
Interest Coverage Ratio: -1.89 > 6 (EBIT TTM -40.0m / Interest Expense TTM 21.1m)
Altman Z'' 1.75
A: 0.19 (Total Current Assets 155.7m - Total Current Liabilities 38.4m) / Total Assets 603.7m
B: -0.01 (Retained Earnings -6.03m / Total Assets 603.7m)
C: -0.05 (EBIT TTM -40.0m / Avg Total Assets 750.4m)
D: 0.82 (Book Value of Equity 204.6m / Total Liabilities 248.2m)
Altman-Z'' = 1.75 = BBB
Beneish M -3.24
DSRI: 1.01 (Receivables 31.1m/27.9m, Revenue 213.0m/192.3m)
GMI: 0.54 (GM 20.86% / 38.87%)
AQI: 1.21 (AQ_t 0.51 / AQ_t-1 0.42)
SGI: 1.11 (Revenue 213.0m / 192.3m)
TATA: -0.07 (NI -65.7m - CFO -25.3m) / TA 603.7m)
Beneish M = -3.24 (Cap -4..+1) = AA
What is the price of MRVI shares?

As of November 16, 2026, the stock is trading at USD 7.54 with a total of 1,992,204 shares traded. Over the past week, the price has changed by +0.27%, over one month by +15.47%, over three months by +30.45% and over the past year by +132.00%.

Current recommended Stop Loss: 6.90 (which is 8.5% or 1.2 ATR below the current price).

Is MRVI a buy, sell or hold?

Maravai Lifesciences has received a consensus analysts rating of 4.11. Therefore, it is recommended to buy MRVI.

  • StrongBuy: 5
  • Buy: 0
  • Hold: 4
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the MRVI price?
Analysts Target Price 8.5 12.7%
Maravai Lifesciences (MRVI) - Fundamental Data Overview as of 16 November 2026
Market Cap USD = 2.59b (2.59b USD * 1.0 USD.USD)
P/E Forward = 212.766
P/S = 12.3822
P/B = 5.6211
Revenue TTM = 213.0m USD
EBIT TTM = -40.0m USD
EBITDA TTM = 20.5m USD
Long Term Debt = 146.0m USD (from longTermDebt, last quarter)
Short Term Debt = 1.12m USD (from shortTermDebt, last quarter)
Debt = 206.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 29.6m
Net Debt = 136.2m USD (calculated: Debt 206.3m - CCE 70.1m)
Enterprise Value = 2.72b USD (2.59b + Debt 206.3m - CCE 70.1m)
Interest Coverage Ratio = -1.89 (Ebit TTM -40.0m / Interest Expense TTM 21.1m)
EV/FCF = -77.51x (Enterprise Value 2.72b / FCF TTM -35.1m)
FCF Yield = -1.29% (FCF TTM -35.1m / Enterprise Value 2.72b)
FCF Margin = -16.48% (FCF TTM -35.1m / Revenue TTM 213.0m)
Net Margin = -30.83% (Net Income TTM -65.7m / Revenue TTM 213.0m)
Gross Margin = 38.87% ((Revenue TTM 213.0m - Cost of Revenue TTM 130.2m) / Revenue TTM)
Gross Margin QoQ = 35.31% (prev 40.14%)
Tobins Q-Ratio = 4.51 (Enterprise Value 2.72b / Total Assets 603.7m)
Interest Expense / Debt = 10.25% (Interest Expense 21.1m / Debt 206.3m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -31.6m (EBIT -40.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.05 (Total Current Assets 155.7m / Total Current Liabilities 38.4m)
Debt / Equity = 1.01 (Debt 206.3m / totalStockholderEquity, last quarter 204.6m)
Debt / EBITDA = 6.64 (Net Debt 136.2m / EBITDA 20.5m)
 Debt / FCF = -3.88 (negative FCF - burning cash) (Net Debt 136.2m / FCF TTM -35.1m)
 Total Stockholder Equity = 218.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -8.75% (Net Income -65.7m / Total Assets 603.7m)
RoE = -30.05% (Net Income TTM -65.7m / Total Stockholder Equity 218.5m)
RoCE = -10.97% (EBIT -40.0m / Capital Employed (Equity 218.5m + L.T.Debt 146.0m))
 RoIC = -5.68% (negative operating profit) (NOPAT -31.6m / Invested Capital 555.8m)
 WACC = 11.33% (E(2.59b)/V(2.79b) * Re(11.59%) + D(206.3m)/V(2.79b) * Rd(10.25%) * (1-Tc(0.21)))
Discount Rate = 11.59% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.47 | Cagr: 4.22%
 [DCF] Fair Price = unknown (Cash Flow -35.1m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.37 | # QB: 0
Revenue Correlation: -86.98 | Revenue CAGR: -14.22% | SUE: 0.41 | # QB: 0
EPS current Quarter (2027-03-31): EPS=-0.00 | Chg30d=N/A | Revisions=-40% | Analysts=5
EPS current Year (2026-12-31): EPS=-0.11 | Chg30d=+39.46% | Revisions=+36% | GrowthEPS=+63.0% | GrowthRev=+14.0%
EPS next Year (2027-12-31): EPS=-0.10 | Chg30d=+4.19% | Revisions=+22% | GrowthEPS=+6.3% | GrowthRev=+6.2%
[Analyst] Revisions Ratio: +21% (up=10, down=6)